

## Billing and Coding Considerations for BLINCYTO®

This Information Sheet is intended to help healthcare professionals understand the key billing and coding considerations for BLINCYTO® and its related services and supplies when using the Food and Drug Administration (FDA)-approved dosing options across treatment settings.

### Updates regarding Medicare Home Infusion Therapy Benefit:

1. Starting January 1, 2021, Medicare implemented the permanent home infusion therapy benefit that provides separate Part B coverage and payment for qualified home infusion therapy services<sup>1</sup>

- Medicare updated the codes used to report the provision of home infusion therapy services
- The new codes differentiate new visits vs subsequent visits for home infusion therapy services
- Claims for home infusion therapy services will be billed separately from the drug, pump, and other supplies. These services must be reported to the A/B Medicare Administrative Contractor (MAC), and are reimbursed by Medicare at rates set by the Medicare Physician Fee Schedule. Claims for the drug, pump, and supplies should continue being sent to the Durable Medical Equipment (DME) MAC and are payable under the Prosthetics, Orthotics, and Supplies (DMEPOS) Fee Schedule<sup>1,2</sup>
- Home infusion therapy services are equal to 5 hours per calendar day, billed in 15 minute increments

Please see pages 10 and 11 for sample claim forms showing coding changes that may be appropriate to report services for Medicare beneficiaries receiving BLINCYTO® treatment via home infusion

2. Due to COVID-19 Public Health Emergency (PHE), Medicare temporarily revised the definition of direct supervision to include the virtual presence of the supervising physician or other qualified healthcare provider using real-time, interactive audio and video telecommunications technology through to December 31, 2024<sup>3</sup>

Medicare sequestration has been fully reinstated beginning with the third quarter of 2022 and as such, the Medicare portion of payment rates are reduced by 2%.<sup>4</sup>

**Please note that the information in this resource is intended to be educational and is not a guarantee of reimbursement. Coverage, coding, and billing requirements vary by health plan so be sure to check with individual payers for detailed guidance.**

### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION

**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- **Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.**
- **Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.**

Please see accompanying BLINCYTO® full Prescribing Information, including **BOXED WARNINGS**. Please see additional Important Safety Information on pages 18-19.

Hospital Inpatient (HIP) Site of Service - Multiple Payers (Medicare and Non-Medicare)

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (ICD-10-CM <sup>7</sup> /HCPCS <sup>8</sup> /CPT <sup>9</sup> /ICD-10-PCS <sup>10</sup> )	Notes
Diagnosis: Encounter for drug therapy and ALL	N/A	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission/failed remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM diagnosis code(s) to describe the patient's condition.
Drug: BLINCYTO® and external infusion pump (EIP)	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>Medicare: 0250</b> General pharmacy</li> <li>• <b>Other payers: 0250 or 0636</b> Drugs requiring detailed coding (if required by a given payer)</li> </ul>	<b>J9039</b> Injection, blinatumomab, 1 mcg	
Administration: Continuous intravenous infusion (CIVI) via EIP	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0290</b> DME</li> </ul>	<b>E0791</b> Parenteral infusion pump, stationary, single or multi-channel <b>E0776</b> IV pole	
	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0261</b> IV therapy: Infusion pump</li> </ul>	<b>3E03305</b> Introduction of other antineoplastic into peripheral vein, percutaneous approach <sup>†</sup> <b>OR</b> <b>3E04305</b> Introduction of other antineoplastic into central vein, percutaneous approach <sup>†</sup> <b>96416</b> Chemotherapy administration, IV infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours) requiring use of a portable or implantable pump <b>OR</b> <b>96521</b> Refilling and maintenance of a portable pump	

Coding Information Definitions:  
 ICD-10-CM – International Classification of Diseases, 10th Revision, Clinical Modification  
 HCPCS – Healthcare Common Procedure Coding System  
 CPT – Current Procedural Terminology  
 ICD-10-PCS – International Classification of Diseases, 10th Revision, Procedure Coding System

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.  
 †The previous ICD-10-PCS codes that described the administration of BLINCYTO® (XW03351 and XW04351) have been deleted and should not be used for dates of service on or after October 1, 2021.

Sample UB-04 (CMS-1450) Form: Hospital Inpatient Administration

**SERVICE UNITS (Field 46):**  
Report units of service for units administered. BLINCYTO® dose reported as 1 unit per mcg

**REVENUE CODES\* (Field 42) and DESCRIPTIONS (Field 43):**  
**Product**  
 Use revenue code **0250** General pharmacy  
**Related supplies and administration procedure**  
 Use the most appropriate revenue code for cost center for services (eg, **0290** Use of DME for EIP and IV pole; eg, **0261** for CIVI therapy [initiation or refill] via EIP)  
 Check payer-specific guidance for additional revenue codes

**PRODUCT AND PROCEDURE CODES (Field 44):**  
 HCPCS codes are only required in outpatient setting  
**Product**  
 Enter the HCPCS code representing BLINCYTO® administered through EIP; eg, **J9039** (blinatumomab) per 1 mcg  
**EIP:** Enter the HCPCS code representing the EIP and supplies used; eg,  

- **E0791** Parenteral infusion pump, stationary, single or multi-channel
- **E0776** IV pole

**DIAGNOSIS CODES\* (Field 67 and 67A-Q):**  
 Enter the appropriate diagnosis code; eg, ICD-10-CM:  

- **Z51.12** Encounter for antineoplastic immunotherapy **AND**
- **C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**
- **C91.01** Acute lymphoblastic leukemia, in remission **OR**
- **C91.02** Acute lymphoblastic leukemia, in relapse

 Final codes depend on medical record documentation and payer requirements

**PRINCIPAL PROCEDURE (Field 74):**  
 Enter principal ICD-10-PCS procedure code  

- **3E03305** Introduction of other antineoplastic into peripheral vein, percutaneous approach<sup>†</sup> **OR**
- **3E04305** Introduction of other antineoplastic into central vein, percutaneous approach<sup>†</sup>

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.  
 †The previous ICD-10-PCS codes that described the administration of BLINCYTO® (XW03351 and XW04351) have been deleted and should not be used for dates of service on or after October 1, 2021.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

**Hospital Outpatient Department (HOPD) - Multiple Payers (Medicare and Non-Medicare)**

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (ICD-10-CM <sup>7</sup> /CPT <sup>9</sup> /HCPCS <sup>8</sup> /NDC <sup>11</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	N/A	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM diagnosis code(s) to describe the patient's condition.
<b>Procedure: Administration via CIVI using an EIP</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0261</b> IV therapy: Infusion pump</li> <li>• <b>026x</b> IV therapy</li> </ul>	<b>96416</b> Chemotherapy administration, IV infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours) requiring use of a portable or implantable pump <b>OR</b> <b>96521</b> Refilling and maintenance of portable pump <b>OR</b> <b>G0498</b> Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion	CPT codes may be used to report the CIVI procedures associated with BLINCYTO® to the Part A/B MAC and non-Medicare payers. For Medicare patients, HCPCS code G0498 will replace CPT and HCPCS codes (96416, E0781, and 99211–99215) previously used to bill for prolonged infusion services when the CIVI is started in the HOPD. It does not apply to BLINCYTO® when the CIVI is started in the inpatient setting or via home infusion. <sup>8,9,12</sup> Certain payers may not recognize G0498 and require itemization of specific items, instead. The healthcare provider should consult the payer or MAC to determine which code is most appropriate for administration of BLINCYTO®. If the clinic bills the G-code to the MAC, the cost of the pump and supplies is bundled and should not be billed separately to the DME MAC. <sup>13</sup>
<b>Drug: BLINCYTO®</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>Medicare: 0636</b> Drug requiring detailed coding</li> <li>• <b>Other payers: 0250 or 0636</b> General pharmacy (if required by a given payer)</li> </ul>	<b>J9039</b> Injection, blinatumomab, 1 mcg <b>JW</b> Discarded drug/not administered to any patient <b>JZ</b> Zero drug amount discarded/not administered to any patient <b>JG</b> Drug or biological acquired with 340B Drug Pricing Program discount <b>TB</b> Drug or biological acquired with 340B Drug Pricing Program discount	Medicare policies reflect the code for BLINCYTO® (J9039 per 1 mcg) and has a maximum utilization of 210 units per date of service (based on prescribing information). <sup>14</sup> However, coding and coverage requirements may vary by payer. Like many payers, Medicare requires the use of the modifier JW and JZ, which provides payment for the amount of drug or biologic discarded, as well as for the dose administered, up to the amount of the drug or biologic as indicated on the vial or label for a single-dose vial (SDV). <sup>15</sup> Note: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologics that are separately payable under Medicare Part B with discarded amounts from single-dose containers. <sup>1</sup> Starting January 1, 2024, CMS is requiring all 340B covered entities, including hospital-based and nonhospital-based entities, that submit claims for separately payable Part B drugs and biologics to report modifier "JG" or "TB" on claim lines for drugs acquired through the 340B Drug Pricing Program. Starting January 1, 2025, 340B covered entities must report the "TB" modifier on claims. <sup>16</sup>
	N/A	<b>NDC: 55513016001</b> BLINCYTO® 35 mcg lyophilized powder, SDV IV solution stabilizer, 10 mL SDV	Some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When reporting the NDC on claims, use the 11-digit NDC in the 5-4-2 format. <sup>17</sup> Insert a leading zero in the appropriate section to complete the 5-4-2 digit format. Remove the dashes prior to entering the NDC on the claim form.

Coding Information Definition:  
NDC – National Drug Code

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.  
<sup>†</sup>Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

**Hospital Outpatient Department (HOPD) - Multiple Payers (Medicare and Non-Medicare) (continued)**

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (HCPCS <sup>8</sup> )	Notes
<b>DME: EIP and supplies</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <b>0290</b> DME	<b>E0779</b> Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater <b>OR</b> <b>E0781</b> Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient <b>OR</b> <b>A4222</b> Infusion supplies for external drug infusion pump, per cassette or bag <b>Modifiers for use with E-codes for IV pump</b> <b>-KD</b> Drug or biologic infused through DME <b>-RR</b> Rental <b>-KH</b> DMEPOS item, initial claim, purchase or first rental month <b>-KI</b> DMEPOS item, second or third rental months <b>-KJ</b> DMEPOS item, parenteral enteral nutrition (pen) pump or capped rental, fourth to 15th rental months	Please note that Medicare specifically requires DMEPOS accreditation in order to bill a DME MAC. Non-Medicare payers may allow billing for all services and supplies under a medical or other benefit. Report the appropriate EIP code and appropriate modifier(s) as documented in the medical record. Modifiers may be used to provide additional detail when billing for the EIP to the DME MAC. <sup>8</sup> Note: Drug administration codes may get billed to the MAC and the E-codes may get billed separately to the DME MAC. Report any supplies as necessary.

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.

Sample UB-04 (CMS-1450) Form: Hospital Outpatient Administration

1 Anytown Hospital 100 Main Street Anytown, Anystate 01010		3a PAT. CTRL. # 3b MED. REC. # 5 FED. TAX. NO.		4 TYPE OF BILL	
8 PATIENT NAME Smith, Jane		9 PATIENT ADDRESS 123 Main Street, Anytown, Anystate 12345			
10 BIRTHDATE		11 SEX		12 DATE	
13 ADMISSION 13 HR 14 TYPE 15 SPO		16 DHR		17 STAT	
18		19		20	
21		22		23	
24		25		26	
27		28		29	
30		31		32	
33		34		35	
36		37		38	
39		40		41	
42		43		44	
45		46		47	
48		49		50	
51		52		53	
54		55		56	
57		58		59	
60		61		62	
63		64		65	
66		67		68	
69		70		71	
72		73		74	
75		76		77	
78		79		80	
81		82		83	
84		85		86	
87		88		89	
90		91		92	
93		94		95	
96		97		98	
99		00		01	
02		03		04	
05		06		07	
08		09		10	
11		12		13	
14		15		16	
17		18		19	
20		21		22	
23		24		25	
26		27		28	
29		30		31	
32		33		34	
35		36		37	
38		39		40	
41		42		43	
44		45		46	
47		48		49	
50		51		52	
53		54		55	
56		57		58	
59		60		61	
62		63		64	
65		66		67	
68		69		70	
71		72		73	
74		75		76	
77		78		79	
80		81		82	
83		84		85	
86		87		88	
89		90		91	
92		93		94	
95		96		97	
98		99		00	
01		02		03	
04		05		06	
07		08		09	
10		11		12	
13		14		15	
16		17		18	
19		20		21	
22		23		24	
25		26		27	
28		29		30	
31		32		33	
34		35		36	
37		38		39	
40		41		42	
43		44		45	
46		47		48	
49		50		51	
52		53		54	
55		56		57	
58		59		60	
61		62		63	
64		65		66	
67		68		69	
70		71		72	
73		74		75	
76		77		78	
79		80		81	
82		83		84	
85		86		87	
88		89		90	
91		92		93	
94		95		96	
97		98		99	
00		01		02	
03		04		05	
06		07		08	
09		10		11	
12		13		14	
15		16		17	
18		19		20	
21		22		23	
24		25		26	
27		28		29	
30		31		32	
33		34		35	
36		37		38	
39		40		41	
42		43		44	
45		46		47	
48		49		50	
51		52		53	
54		55		56	
57		58		59	
60		61		62	
63		64		65	
66		67		68	
69		70		71	
72		73		74	
75		76		77	
78		79		80	
81		82		83	
84		85		86	
87		88		89	
90		91		92	
93		94		95	
96		97		98	
99		00		01	
02		03		04	
05		06		07	
08		09		10	
11		12		13	
14		15		16	
17		18		19	
20		21		22	
23		24		25	
26		27		28	
29		30		31	
32		33		34	
35		36		37	
38		39		40	
41		42		43	
44		45		46	
47		48		49	
50		51		52	
53		54		55	
56		57		58	
59		60		61	
62		63		64	
65		66		67	
68		69		70	
71		72		73	
74		75		76	
77		78		79	
80		81		82	
83		84		85	
86		87		88	
89		90		91	
92		93		94	
95		96		97	
98		99		00	
01		02		03	
04		05		06	
07		08		09	
10		11		12	
13		14		15	
16		17		18	
19		20		21	
22		23		24	
25		26		27	
28		29		30	
31		32		33	
34		35		36	
37		38		39	
40		41		42	
43		44		45	
46		47		48	
49		50		51	
52		53		54	
55		56		57	
58		59		60	
61		62		63	
64		65		66	
67		68		69	
70		71		72	
73		74		75	
76		77		78	
79		80		81	
82		83		84	
85		86		87	
88		89		90	
91		92		93	
94		95		96	
97		98		99	
00		01		02	
03		04		05	
06		07		08	
09		10		11	
12		13		14	
15		16		17	
18		19		20	
21		22		23	
24		25		26	
27		28		29	
30		31		32	
33		34		35	
36		37		38	
39		40		41	
42		43		44	
45		46		47	
48		49		50	
51		52		53	
54		55		56	
57		58		59	
60		61		62	
63		64		65	
66		67		68	
69		70		71	
72		73		74	
75		76		77	
78		79		80	
81		82		83	
84		85		86	
87		88		89	
90		91		92	
93		94		95	
96		97		98	
99		00		01	
02		03		04	
05		06		07	
08		09		10	
11		12		13	
14		15		16	
17		18		19	
20		21		22	
23		24		25	
26		27		28	
29		30		31	
32		33		34	
35		36		37	
38		39		40	
41		42		43	
44		45		46	
47		48		49	
50		51		52	
53		54		55	
56		57		58	
59		60		61	
62		63		64	
65		66		67	
68		69		70	
71		72		73	
74		75		76	
77		78		79	
80		81		82	
83		84		85	
86		87		88	
89		90		91	
92		93		94	
95		96		97	
98		99		00	
01		02		03	
04		05		06	
07		08		09	
10		11		12	
13		14		15	
16		17		18	
19		20		21	
22		23		24	
25		26		27	
28		29		30	
31		32		33	
34		35		36	
37		38		39	
40		41		42	
43		44		45	
46		47		48	
49		50		51	
52		53		54	
55		56		57	
58		59		60	
61		62		63	
64		65		66	
67		68		69	
70		71		72	
73		74		75	
76		77		78	
79		80		81	
82		83		84	
85		86		87	
88		89		90	
91		92		93	
94		95		96	
97		98		99	
00		01		02	
03		04		05	
06		07		08	
09		10		11	
12</					

# BLINCYTO® Billing Information Sheet

## Sample CMS-1500 Form: Physician Office Administration



## Home Infusion - Multiple Payers (Medicare and Non-Medicare)

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) (12/12)

1. MEDICARE (Medicare#)  MEDICAID (Medicaid#)  TRICARE (ID#/DoD#)  CHAMPVA (Member ID#)  GROUP HEALTH PLAN (ID#)  FECA (ID#)  OTHER (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX (M/F)

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED (Self, Spouse, Child, Other)

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO: (a. EMPLOYMENT?, b. AUTO ACCIDENT?, c. OTHER ACCIDENT?)

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. INSURED'S DATE OF BIRTH (MM/DD/YY) SEX (M/F)

13. OTHER CLAIM ID (Designated by NUCC)

14. INSURANCE PLAN NAME OR PROGRAM NAME

15. CLAIM CODE

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below)

23. PRIOR AUTHORIZATION NUMBER

24. A. DATE(S) OF SERVICE (From MM/DD/YY To MM/DD/YY) B. PLACE OF SERVICE (EMG) C. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) D. CHARGES (CPT/HCPCS) E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS (CP UNITS) H. REPORT (UNIT) I. ID. (UNIT) J. (UNIT)

1	MM	DD	YY	MM	DD	YY	11	J9039		A B	XXX	XX	X	NPI
2								J9039	JW	A B	XXX	XX	X	NPI
3							11	96419		A B	XXX	XX	1	NPI

**NDC (BOX 24A SHADED AREA):** When reporting BLINCYTO®, some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When required by the payer, report the NDC qualifier "N4," indicating that an NDC follows, and the NDC in the 11-digit format. The unit of measure can also be reported, 3 spaces after the NDC, as UNX (X = the number of vials). Verify the payer-specific claim submission requirements

**DIAGNOSIS (BOX 21):** Enter the appropriate diagnosis code; eg, ICD-10-CM:

- **Z51.12** Encounter for antineoplastic immunotherapy **AND**
- **C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**
- **C91.01** Acute lymphoblastic leukemia, in remission **OR**
- **C91.02** Acute lymphoblastic leukemia, in relapse

Final codes depend on medical record documentation

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**UNITS (Box 24G):** Report units of service for both units administered and amount of discarded drug. BLINCYTO® dose reported as 1 unit per mcg. Report 1 unit for initiation of CIVI via EIP or refill of EIP

**PLACE OF SERVICE (Box 24B):** Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg, • **11** Physician office

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):** Enter the appropriate administration procedure. Use the CPT code representing the procedure performed, such as initiation OR refill; eg, **96416** Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump **OR** **96521** Refilling and maintenance of portable pump **OR** **G0498** Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion **JW/JZ Discard Modifier:** JW or JZ modifier required for Medicare Part B claims for drugs in single-use containers

Item	Coding Information (ICD-10-CM <sup>7</sup> /CPT <sup>9</sup> /HCPCS <sup>8</sup> /NDC <sup>11</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM code(s) to describe the patient's condition.
<b>Procedure: Administration via CIVI using an EIP</b>	<b>G0090</b> Professional services, initial visit, for the administration of intravenous chemotherapy or other highly complex infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes <sup>1</sup> <b>G0070</b> Professional services for the administration of intravenous chemotherapy or other intravenous highly complex drug or biological infusion for each infusion drug administration calendar day in the individual's home, each 15 minutes <sup>1</sup> <b>99601</b> Home infusion/specialty drug administration, per visit (up to 2 hours) <b>99602</b> Each additional hour <b>S9329</b> Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9330</b> Home infusion therapy, continuous (24 hours or more) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9338</b> Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9379</b> Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	Home infusion therapy services for Medicare beneficiaries receiving BLINCYTO® should be billed using G0090 for an initial visit and G0070 for subsequent visits. Some or all Medicare contractors may reject chemotherapy CPT codes with the availability of G0070 and G0090. These services must be reported to the A/B MAC, and are reimbursed by Medicare at rates set by the Medicare Physician Fee Schedule. They are billed and paid separately from the external infusion pump and drug, which are billed to the DME MAC and reimbursed under the DMEPOS Fee Schedule. Medicare requires that a claim for BLINCYTO® be billed no more than 30 days prior to the visit. Otherwise, payment for the home infusion therapy service will be denied. <sup>1</sup> These services may be covered by Medicaid, commercial plans, or Medicare Advantage plans. <sup>20</sup> CPT codes 99601 and 99602, as well as certain S-codes, may be used to report home infusion therapy services to other payer types other than FFS Medicare. Please note that FFS Medicare does not recognize S-codes, although other payers might. <sup>20</sup>
<b>Drug: BLINCYTO®</b>	<b>J9039</b> Injection, blinatumomab, 1 mcg <b>JW</b> Discarded drug/not administered to any patient <b>JZ</b> Zero drug amount discarded/not administered to any patient	Medicare requires that claims for BLINCYTO®, the pump, and supplies be sent to the DME MACs. Claims for home infusion therapy services must now be submitted separately and are processed by Part A/B MACs. <sup>1</sup> Medicare sets maximum utilization at 875 units of service (UOS), which is equivalent to 25 vials per month in this site of care. <sup>21</sup> Many payers require the use of the modifier JW and JZ, which provides payment for the amount of drug or biologic discarded, as well as for the dose administered, up to the amount of the drug or biologic as indicated on the vial or label for an SDV. <sup>15</sup> Note: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers.*
<b>DME: EIP and supplies</b>	<b>E0779</b> Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater <sup>22</sup> <b>E0781</b> Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient <sup>22</sup> <b>A4222</b> Infusion supplies for external drug infusion pump, per cassette or bag <b>Modifiers for EIP</b> <b>-KD</b> Drug or biologic infused through DME <b>-RR</b> Rental <b>-KH</b> DMEPOS item, initial claim or first rental month <b>-KI</b> DMEPOS item, second or third rental months <b>-KJ</b> DMEPOS item, fourth to 15th rental months	Report the appropriate EIP code and appropriate modifier(s) as documented in the medical record. Modifiers may be used to provide additional detail when billing for the EIP to the DME MAC. <sup>8</sup> Report any supplies as necessary.
	<b>NDC: 55513016001</b> BLINCYTO® 35 mcg lyophilized powder, SDV IV solution stabilizer, 10 mL SDV	Some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When reporting the NDC on claims, use the 11-digit NDC in the 5-4-2 format. <sup>17</sup> Insert a leading zero in the appropriate section to complete the 5-4-2 digit format. Remove the dashes prior to entering the NDC on the claim form.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.  
Please see Important Safety Information for BLINCYTO® on pages 18-19.

Sample CMS-1500 Form: Medicare DME MAC for BLINCYTO®, Pump, and Related Supplies by DME Supplier

Sample CMS-1500 form: Medicare A/B MAC for Home Infusion Therapy Services by Home Infusion Therapy Supplier

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) (2/12)

1. MEDICARE (Medicare#)  MEDICAID (Medicaid#)  TRICARE (ID#/DoD#)  CHAMPVA (Member ID#)  GROUP HEALTH PLAN (ID#)  FECA BLK LUNG (ID#)  OTHER (ID#)

1a. INSURED'S I.D. NUMBER (For Program in Item 1)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX (M/F)

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

6. PATIENT RELATIONSHIP TO INSURED: Self  Spouse  Child  Other

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

**DIAGNOSIS (Box 21):**  
Enter the appropriate diagnosis code; eg, ICD-10-CM:  
**Z51.12** Encounter for antineoplastic immunotherapy **AND**  
**C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**  
**C91.01** Acute lymphoblastic leukemia, in remission **OR**  
**C91.02** Acute lymphoblastic leukemia, in relapse  
Final codes depend on medical record documentation

1. NDC	2. DATE(S) OF SERVICE	3. PLACE OF SERVICE	4. PROCEDURES, SERVICES, OR SUPPLIES	5. CHARGES	6. UNITS	7. DISCARD	8. SUPPLIER
N45513016001 UNX	MM DD YY MM DD YY 12	J9039	A B	XXX XX X			
N45513016001 UNX	MM DD YY MM DD YY 12	J9039 JW	A B	XXX XX X			
	MM DD YY MM DD YY 12	E0781 RR KH	A B	XXX XX 1			
	MM DD YY MM DD YY 12	A4222	A B				

**PLACES OF SERVICE (Box 24B):**  
Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg,  
• 12 Home

**UNITS (Box 24G):**  
Report units of service for both units administered and amount of discarded drug. BLINCYTO® dose reported as 1 unit per mcg. Report 1 unit each for EIP and other supplies

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):**  
Enter the appropriate CPT/HCPCS codes and modifiers; eg,  
• Drug: **J9039** for BLINCYTO®  
**JW/JZ Discard Modifier:** JW or JZ modifier required for Medicare DME external infusion pump claims including infused drugs in single-use containers  
• IV Pump: **E0781** Ambulatory infusion pump  
• **A4222** Infusion supplies for external drug infusion pump, per cassette or infusion option  
Other codes may be appropriate. Check with individual Medicare DME MACs for detailed guidance

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) (2/12)

1. MEDICARE (Medicare#)  MEDICAID (Medicaid#)  TRICARE (ID#/DoD#)  CHAMPVA (Member ID#)  GROUP HEALTH PLAN (ID#)  FECA BLK LUNG (ID#)  OTHER (ID#)

1a. INSURED'S I.D. NUMBER (For Program in Item 1)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX (M/F)

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

6. PATIENT RELATIONSHIP TO INSURED: Self  Spouse  Child  Other

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

**DIAGNOSIS (Box 21):**  
Enter the appropriate diagnosis code; eg, ICD-10-CM:  
**Z51.12** Encounter for antineoplastic immunotherapy **AND**  
**C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**  
**C91.01** Acute lymphoblastic leukemia, in remission **OR**  
**C91.02** Acute lymphoblastic leukemia, in relapse  
Final codes depend on medical record documentation

1. NDC	2. DATE(S) OF SERVICE	3. PLACE OF SERVICE	4. PROCEDURES, SERVICES, OR SUPPLIES	5. CHARGES	6. UNITS	7. DISCARD	8. SUPPLIER
	MM DD YY MM DD YY 12	G0090	A B	XXX XX X			
	MM DD YY MM DD YY 12	J9039	A B	0 00 X			

**PLACES OF SERVICE (Box 24B):**  
Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg,  
• 12 Home

**UNITS (Box 24G):**  
Report units of service for the administration of BLINCYTO®, reported as 1 unit per 15 minutes of time of IV infusion

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):**  
Enter the appropriate CPT/HCPCS codes and modifiers; eg,  
• IV Infusion: **G0090** for IV infusion of BLINCYTO®, initial visit  
• Drug: **J9039** is added to identify BLINCYTO® as the drug related to the administration service; List a zero charge to indicate that no reimbursement for the drug is expected  
Other codes may be appropriate. Check with individual Medicare A/B MAC for detailed guidance

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Sample CMS-1500 Form: Non-Medicare Payer by Home Infusion Provider

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 1/2/12

1. MEDICARE (Medicare #), MEDICAID (Medicaid #), TRICARE (ID#/Dx/D#), CHAMPVA (Member ID#), GROUP HEALTH PLAN (ID#), FECA BLK LUNG (ID#), OTHER (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY), SEX (M/F)

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street), CITY, STATE, ZIP CODE, TELEPHONE (Include Area Code)

6. PATIENT RELATIONSHIP TO INSURED (Self, Spouse, Child, Other)

7. INSURED'S ADDRESS (No., Street), CITY, STATE, ZIP CODE, TELEPHONE (Include Area Code)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE

14. DATE (MM/DD/YY)

15. DATE(S) OF SERVICE (From MM/DD/YY To MM/DD/YY)

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION (FROM MM/DD/YY TO MM/DD/YY)

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below)

24. A. DATE(S) OF SERVICE, B. PLACE OF SERVICE, C. EMERGENCY, D. PROCEDURES, SERVICES, OR SUPPLIES (CPT/HCPCS), E. DIAGNOSIS POINTER, F. \$ CHARGES, G. DAYS UNITS

**NDC (BOX 24A SHADED AREA):** When required by the payer, report the NDC qualifier "N4," indicating that an NDC follows, and the NDC in the 11-digit format. The unit of measure can also be reported, 3 spaces after the NDC, as UNX (X = the number of vials). Verify the payer-specific claim submission requirements

**DIAGNOSIS (BOX 21):** Enter the appropriate diagnosis code; eg, ICD-10-CM:  
 • Z51.12 Encounter for antineoplastic immunotherapy AND  
 • C91.00 Acute lymphoblastic leukemia not having achieved remission OR  
 • C91.01 Acute lymphoblastic leukemia, in remission OR  
 • C91.02 Acute lymphoblastic leukemia, in relapse  
 Final codes depend on medical record documentation

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**UNITS (Box 24G):** Report units of service for both units of drug administered and amount of discarded drug. BLINCYTO® dose reported with 1 unit per 1 mcg

**PLACE OF SERVICE (Box 24B):** Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg,  
 • 12 Home

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):** Enter the appropriate CPT/HCPCS codes and modifiers; eg,  
 • Drug: J9039 for BLINCYTO®  
 • 99601 Home infusion/specialty drug administration, per visit (up to 2 hours)  
 • A4222 Infusion supplies for external drug infusion pump, per cassette or infusion option  
 Other codes may be appropriate. Check with individual payers for detailed guidance  
 NOTE: Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

**BLINCYTO® Dosing Options<sup>11</sup>**

Dosing option	Dose per vial X number of SDVs*	Number of billing units
24-hour	35 mcg X 1 vial	35
48-hour	35 mcg X 1-2 vials	35-70
7-day	35 mcg X 4-6 vials	140-210

\*Number of SDVs depends on dose, infusion duration, and patient's weight.<sup>11</sup>

**Key Considerations for the BLINCYTO® 7-day Infusion Option (7-DIO)**



Minor variations are expected in coding, billing, and claims filing for the BLINCYTO® 7-DIO.<sup>20</sup>



The 7-DIO requires 6 vials of BLINCYTO® and 1 vial of IV Solution Stabilizer for patients ≥ 45 kg. For patients weighing less than 45 kg, 4 to 5 vials are required. The safety of the administration of BLINCYTO® at a BSA of less than 0.4 m<sup>2</sup> has not been established.<sup>11</sup> Refer to the Prescribing Information for details on handling and preparation.



If the units field on a claim form cannot accommodate more than 99 units, utilize multiple lines to capture all units (eg, 99+98+13). Payers may require separate reporting of drug units administered and discarded.<sup>20</sup>



Less frequent claim submissions are expected with utilization of the 7-DIO. Typically the entire 7-DIO can be billed on the day of administration/refill. However, be sure to refer to payer guidelines for maximum daily quantity limits. Apply the appropriate dates of service as needed.<sup>20</sup>



If the 7-DIO is interrupted mid-treatment, refer to payer guidelines for reporting and documentation in these cases. If full reimbursement is withheld by the payer, refer to Amgen's Product Return Policy for assistance.



Existing codes and modifiers are adequate to report BLINCYTO® and its related services; however, payer requirements may vary with respect to:<sup>20</sup>

- The entities that can bill for DME and the associated supplies
- The number of units billed for BLINCYTO® J9039 (HCPCS units vs number of vials)
- Covered diagnosis codes
- Covered nursing services (eg, infusion services at patient's home)
- Drug claim submission options (eg, 1 or more dates of service on claims)
- Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

# UNDERSTANDING EXAMPLES OF



## REIMBURSEMENT ACROSS SITES OF CARE

A BLINCYTO® patient transitions through multiple sites of care. This guide shows how major payers in the United States (commercial plans, Medicare, and Medicaid) offer coverage in each setting and reimburse for each component of care:



Drug



Pump and Supplies



Hospitalization



Professional Services (ie, drug administration)

### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION


**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.
- Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.

Please see additional Important Safety Information for BLINCYTO® on pages 18-19.

## BLINCYTO® (blinatumomab) Reimbursement Process

Coverage of BLINCYTO® and its administration is required in all these sites of care to avoid interruption in treatment.



The scenarios depicted above illustrate the most common ones for accessing BLINCYTO® via the buy-and-bill acquisition process, where the entity that acquires the product also administers it to the patient.





BLINCYTO® can also be acquired via a specialty pharmacy provider, including:

- Third-party specialty pharmacies that contract with a payer to supply specialty products covered under the medical benefit
- Specialty pharmacies owned by hospitals, physician offices, ambulatory infusion clinics, and/or home infusion companies that may also administer the medication






# BLINCYTO® Reimbursement Across Transitions in Site of Care




BLINCYTO®-eligible patients need coverage for the following: Drug + Pump + Hospitalization + Administration

Inpatient Hospital			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	MS-DRG-based or global payment; typically includes BLINCYTO® <sup>23</sup>	MS-DRG payment includes BLINCYTO® <sup>24</sup>	APR-DRG-based payment; typically includes BLINCYTO® <sup>27</sup>
<b>Pump and Supplies</b> 	Reimbursement varies by contracts between providers and payers  Some hospitals, in their contracts with managed care organizations, may negotiate a “carve out” benefit for drugs such as BLINCYTO® • May allow separate payment of such drugs outside of the bundled payment for inpatient services	Covered under Medicare Part A benefit <sup>25</sup>  Hospital may be eligible for outlier payments if cost of admission exceeds certain threshold	Reimbursement varies by state; may follow Medicare allowable amounts
<b>Hospitalization</b> 		Reimbursement varies for the 11 IPPS-Exempt Cancer Hospitals <sup>26</sup>	
<b>Professional Services</b> 	Physician services may be covered separately outside of the bundled payment	Physician services may be covered and reimbursed according to the MPFS under Medicare Part B benefit	Physician services may be covered and paid outside of the bundled payment




Key: APR-DRG – All Patient-Refined Diagnosis Related Groups; FFS – fee-for-service; IPPS – Inpatient Prospective Payment System; MPFS – Medicare Physician Fee Schedule; MS-DRG – Medicare Severity Diagnosis-Related Group.

Outpatient Hospital			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	Reimbursed based on contracted rates; methodology varies Examples: <sup>28</sup> • ASP + X% • WAC + X% • AWP – X%  May need prior authorization	Covered under Medicare Part B benefit  Typically reimbursed based on ASP + 6% when administered in a 340B hospital setting (with 2% sequestration reduction) <sup>29,30</sup>  MUE cap of 210 units (approx. 6 vials) per date of service applies <sup>31,8</sup>	Reimbursement may be similar to Medicare  OR State-defined limit (eg, California uses a federal upper limit) <sup>32</sup>  May need prior authorization
<b>Pump and Supplies</b> 	Reimbursement is bundled into the payment for the infusion service	Covered under Medicare Part B benefit  Reimbursement is bundled into the payment for the infusion service	Reimbursed based on fee schedule or bundled into the payment for the infusion service  Rates vary by state
<b>Professional Services</b> 	Reimbursed based on contracted rate	Reimbursed based on the Medicare OPSS	

Key: ASP – average sales price; AWP – average wholesale price; FFS – fee-for-service; MUE – medically unlikely edit; OPSS – Outpatient Prospective Payment System; WAC – wholesale acquisition cost.  
Note: The information here describes coverage and payment for BLINCYTO® under FFS Medicare and FFS Medicaid. Coverage and payment for patients enrolled in Medicare Advantage and/or Medicaid managed care organizations varies widely and is often similar to commercial insurance.

Physician Office			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	Reimbursed based on contracted rates; methodology varies Examples: <sup>28</sup> • ASP + X% • WAC + X% • AWP – X%  May need prior authorization	Covered under Medicare Part B benefit  Typically reimbursed based on ASP + 6% (with 2% sequestration reduction) <sup>30,33</sup>  MUE cap of 210 units (approx. 6 vials) per date of service applies <sup>8,19</sup>	Reimbursement may be similar to Medicare  OR State-defined limit (eg, California uses a federal upper limit) <sup>32</sup>  May need prior authorization
<b>Pump and Supplies</b> 	Reimbursed based on contracted rate and bundled into payment for the infusion service	Covered under Medicare Part B benefit  Reimbursement is bundled into the payment for the infusion service	Typically reimbursed based on fee schedule or bundled into the payment for the infusion service  Rates vary by state
<b>Professional Services</b> 	Reimbursed based on contracted rate	Reimbursed based on the MPFS	

Key: ASP – average sales price; AWP – average wholesale price; FFS – fee-for-service; MPFS – Medicare Physician Fee Schedule; MUE – medically unlikely edit; WAC – wholesale acquisition cost.

Home Infusion			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	Reimbursed based on contracted rates; methodology varies Examples: <sup>28</sup> • ASP + X% • WAC + X% • AWP – X%  May need prior authorization	Covered under Medicare Part B as long as it is supplied in a covered external infusion pump and the IV is initiated in home infusion setting <sup>34</sup>  Typically reimbursed based on ASP + 6% (with 2% sequestration reduction) <sup>30,33</sup>  Billing cap of 25 vials per month applies <sup>21</sup>	Reimbursement may be similar to Medicare  OR State-defined limit (eg, California uses a federal upper limit) <sup>37</sup>  May need prior authorization
<b>Pump and Supplies</b> 	Reimbursed based on contracted rate	Covered under Medicare Part B benefit  Reimbursed as part of the Medicare DMEPOS Fee Schedule <sup>35</sup>	Typically reimbursed based on fee schedule  Rates vary by state
<b>Professional Services</b> 	Reimbursed based on contracted rate	Covered under Part B  Reimbursed under the home infusion therapy services benefit in 15-minute increments for applicable providers <sup>36</sup>	

Key: ASP – average sales price; AWP – average wholesale price; DMEPOS – Durable Medical Equipment Prosthetics, Orthotics, and Supplies; FFS – fee-for-service; WAC – wholesale acquisition cost.  
Note: Medicare home infusion benefit is distinct and separate from the Medicare home health benefit.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO®

## Indications and Important Safety Information



### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION

**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- **Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.**
- **Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.**

### Contraindications

BLINCYTO® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.

### Warnings and Precautions

- **Cytokine Release Syndrome (CRS):** CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin, and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO, CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO® until CRS resolves. Discontinue BLINCYTO® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS.

- **Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome:** BLINCYTO® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO®, but some resulted in treatment discontinuation.

The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO® therapy.

Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities.

- **Infections:** Approximately 25% of patients receiving BLINCYTO® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO® as needed.
- **Tumor Lysis Syndrome (TLS),** which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cyto-reduction and on-treatment hydration, should be used during BLINCYTO® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO® as needed to manage these events.
- **Neutropenia and Febrile Neutropenia,** including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO® infusion and interrupt BLINCYTO® if prolonged neutropenia occurs.
- **Effects on Ability to Drive and Use Machines:** Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO® is being administered.
- **Elevated Liver Enzymes:** Transient elevations in liver enzymes have been associated with BLINCYTO® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO®, although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than

### IMPORTANT SAFETY INFORMATION (continued)

1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO® treatment. BLINCYTO® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN.

- **Pancreatitis:** Fatal pancreatitis has been reported in patients receiving BLINCYTO® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO® and dexamethasone as needed.
- **Leukoencephalopathy:** Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO®, especially in patients previously treated with cranial irradiation and antileukemic chemotherapy.
- **Preparation and administration** errors have occurred with BLINCYTO® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose).
- **Immunization:** Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO®.
- **Benzyl Alcohol Toxicity in Neonates:** Serious adverse reactions, including fatal reactions and the “gasping syndrome,” have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

Use the preservative-free preparations of BLINCYTO® where possible in neonates. When prescribing BLINCYTO® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway.

Monitor neonatal patients receiving BLINCYTO® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO® 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL.

- **Embryo-Fetal Toxicity:** Based on its mechanism of action, BLINCYTO® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO® and for 48 hours after the last dose.

### Adverse Reactions

- The safety of BLINCYTO® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.

### Dosage and Administration Guidelines

- BLINCYTO® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm.
- It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose).

**Please see accompanying BLINCYTO® full Prescribing Information, including BOXED WARNINGS.**

**Please note:** The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for their own patients and procedures. In no way should the information provided in this document be considered a guarantee of coverage or reimbursement for any product or service.



## Billing and Coding Considerations for BLINCYTO®

This Information Sheet is intended to help healthcare professionals understand the key billing and coding considerations for BLINCYTO® and its related services and supplies when using the Food and Drug Administration (FDA)-approved dosing options across treatment settings.

### Updates regarding Medicare Home Infusion Therapy Benefit:

1. Starting January 1, 2021, Medicare implemented the permanent home infusion therapy benefit that provides separate Part B coverage and payment for qualified home infusion therapy services<sup>1</sup>

- Medicare updated the codes used to report the provision of home infusion therapy services
- The new codes differentiate new visits vs subsequent visits for home infusion therapy services
- Claims for home infusion therapy services will be billed separately from the drug, pump, and other supplies. These services must be reported to the A/B Medicare Administrative Contractor (MAC), and are reimbursed by Medicare at rates set by the Medicare Physician Fee Schedule. Claims for the drug, pump, and supplies should continue being sent to the Durable Medical Equipment (DME) MAC and are payable under the Prosthetics, Orthotics, and Supplies (DMEPOS) Fee Schedule<sup>1,2</sup>
- Home infusion therapy services are equal to 5 hours per calendar day, billed in 15 minute increments

Please see pages 10 and 11 for sample claim forms showing coding changes that may be appropriate to report services for Medicare beneficiaries receiving BLINCYTO® treatment via home infusion

2. Due to COVID-19 Public Health Emergency (PHE), Medicare temporarily revised the definition of direct supervision to include the virtual presence of the supervising physician or other qualified healthcare provider using real-time, interactive audio and video telecommunications technology through to December 31, 2024<sup>3</sup>

Medicare sequestration has been fully reinstated beginning with the third quarter of 2022 and as such, the Medicare portion of payment rates are reduced by 2%.<sup>4</sup>

**Please note that the information in this resource is intended to be educational and is not a guarantee of reimbursement. Coverage, coding, and billing requirements vary by health plan so be sure to check with individual payers for detailed guidance.**

### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION

**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- **Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.**
- **Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.**

[Click here](#) to see BLINCYTO® full Prescribing Information, including **BOXED WARNINGS**. Please see additional Important Safety Information on pages 18-19.

# BLINCYTO®

## Billing Information Sheet



### Hospital Inpatient (HIP) Site of Service - Multiple Payers (Medicare and Non-Medicare)

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (ICD-10-CM <sup>7</sup> /HCPCS <sup>8</sup> /CPT <sup>9</sup> /ICD-10-PCS <sup>10</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	N/A	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission/failed remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM diagnosis code(s) to describe the patient's condition.
<b>Drug: BLINCYTO® and external infusion pump (EIP)</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>Medicare: 0250</b> General pharmacy</li> <li>• <b>Other payers: 0250 or 0636</b> Drugs requiring detailed coding (if required by a given payer)</li> </ul>	<b>J9039</b> Injection, blinatumomab, 1 mcg	
	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0290</b> DME</li> </ul>	<b>E0791</b> Parenteral infusion pump, stationary, single or multi-channel <b>E0776</b> IV pole	
<b>Administration: Continuous intravenous infusion (CIVI) via EIP</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0261</b> IV therapy: Infusion pump</li> </ul>	<b>3E03305</b> Introduction of other antineoplastic into peripheral vein, percutaneous approach <sup>†</sup> <b>OR</b> <b>3E04305</b> Introduction of other antineoplastic into central vein, percutaneous approach <sup>†</sup> <b>96416</b> Chemotherapy administration, IV infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours) requiring use of a portable or implantable pump <b>OR</b> <b>96521</b> Refilling and maintenance of a portable pump	

#### Coding Information Definitions:

ICD-10-CM – International Classification of Diseases, 10th Revision, Clinical Modification

HCPCS – Healthcare Common Procedure Coding System

CPT – Current Procedural Terminology

ICD-10-PCS – International Classification of Diseases, 10th Revision, Procedure Coding System

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.

†The previous ICD-10-PCS codes that described the administration of BLINCYTO® (XW03351 and XW04351) have been deleted and should not be used for dates of service on or after October 1, 2021.

# BLINCYTO® Billing Information Sheet



## Sample UB-04 (CMS-1450) Form: Hospital Inpatient Administration

1 Anytown Hospital 100 Main Street Anytown, Anystate 01010		2		3a PAT. CNTRL. # b. MED. REC. # 5 FED. TAX ID #		4 TYPE OF BILL	
8 PATIENT NAME Smith, Jane				9 PATIENT ADDRESS 123 Main Street, Anytown, Anystate 12345			
10 BIRTHDATE		11 SEX		12 DATE		ADMISSION 13 HR 14 TYPE 15 SRC 16 DHR 17 STAY	
18		19		20		21	
22		23		24		25	
26		27		28		29	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834		835		836		837	
838		839		840		841	
842		843		844		845	
846		847		848		849	
850		851		852		853	
854		855		856		857	
858		859		860		861	
862		863		864		865	
866		867		868		869	
870		871		872		873	
874		875		876		877	
878		879		880		881	
882		883		884		885	
886		887		888		889	
890		891		892			

# BLINCYTO®

## Billing Information Sheet



### Hospital Outpatient Department (HOPD) - Multiple Payers (Medicare and Non-Medicare)

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (ICD-10-CM <sup>7</sup> /CPT <sup>9</sup> /HCPCS <sup>8</sup> /NDC <sup>11</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	N/A	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM diagnosis code(s) to describe the patient's condition.
<b>Procedure: Administration via CIVI using an EIP</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>0261</b> IV therapy: Infusion pump</li> <li>• <b>026x</b> IV therapy</li> </ul>	<b>96416</b> Chemotherapy administration, IV infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours) requiring use of a portable or implantable pump <b>OR</b> <b>96521</b> Refilling and maintenance of portable pump <b>OR</b> <b>G0498</b> Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion	CPT codes may be used to report the CIVI procedures associated with BLINCYTO® to the Part A/B MAC and non-Medicare payers. For Medicare patients, HCPCS code G0498 will replace CPT and HCPCS codes (96416, E0781, and 99211–99215) previously used to bill for prolonged infusion services when the CIVI is started in the HOPD. It does not apply to BLINCYTO® when the CIVI is started in the inpatient setting or via home infusion. <sup>8,9,12</sup> Certain payers may not recognize G0498 and require itemization of specific items, instead. The healthcare provider should consult the payer or MAC to determine which code is most appropriate for administration of BLINCYTO®. If the clinic bills the G-code to the MAC, the cost of the pump and supplies is bundled and should not be billed separately to the DME MAC. <sup>13</sup>
<b>Drug: BLINCYTO®</b>	Report the appropriate revenue code for the cost center in which the service is performed; eg, <ul style="list-style-type: none"> <li>• <b>Medicare: 0636</b> Drug requiring detailed coding</li> <li>• <b>Other payers: 0250 or 0636</b> General pharmacy (if required by a given payer)</li> </ul>	<b>J9039</b> Injection, blinatumomab, 1 mcg <b>JW</b> Discarded drug/not administered to any patient <b>JZ</b> Zero drug amount discarded/not administered to any patient <b>JG</b> Drug or biological acquired with 340B Drug Pricing Program discount <b>TB</b> Drug or biological acquired with 340B Drug Pricing Program discount	Medicare policies reflect the code for BLINCYTO® (J9039 per 1 mcg) and has a maximum utilization of 210 units per date of service (based on prescribing information). <sup>14</sup> However, coding and coverage requirements may vary by payer. Like many payers, Medicare requires the use of the modifier JW and JZ, which provides payment for the amount of drug or biologic discarded, as well as for the dose administered, up to the amount of the drug or biologic as indicated on the vial or label for a single-dose vial (SDV). <sup>15</sup> Note: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers. <sup>†</sup> Starting January 1, 2024, CMS is requiring all 340B covered entities, including hospital-based and nonhospital-based entities, that submit claims for separately payable Part B drugs and biologicals to report modifier "JG" or "TB" on claim lines for drugs acquired through the 340B Drug Pricing Program. Starting January 1, 2025, 340B covered entities must report the "TB" modifier on claims. <sup>16</sup>
	N/A	<b>NDC: 55513016001</b> BLINCYTO® 35 mcg lyophilized powder, SDV IV solution stabilizer, 10 mL SDV	Some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When reporting the NDC on claims, use the 11-digit NDC in the 5-4-2 format. <sup>17</sup> Insert a leading zero in the appropriate section to complete the 5-4-2 digit format. Remove the dashes prior to entering the NDC on the claim form.

Coding Information Definition:  
NDC – National Drug Code

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.

†Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

**BLINCYTO®**  
**Billing Information Sheet**



**Hospital Outpatient Department (HOPD) - Multiple Payers (Medicare and Non-Medicare) (continued)**

Item	Revenue Code <sup>5,6,*</sup>	Coding Information (HCPCS <sup>2</sup> )	Notes
<p><b>DME: EIP and supplies</b></p>	<p>Report the appropriate revenue code for the cost center in which the service is performed; eg, <b>0290</b> DME</p>	<p><b>E0779</b> Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater <b>OR</b>  <b>E0781</b> Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient <b>OR</b>  <b>A4222</b> Infusion supplies for external drug infusion pump, per cassette or bag  <b>Modifiers for use with E-codes for IV pump</b>  <b>-KD</b> Drug or biologic infused through DME  <b>-RR</b> Rental  <b>-KH</b> DMEPOS item, initial claim, purchase or first rental month  <b>-KI</b> DMEPOS item, second or third rental months  <b>-KJ</b> DMEPOS item, parenteral enteral nutrition (pen) pump or capped rental, fourth to 15th rental months</p>	<p>Please note that Medicare specifically requires DMEPOS accreditation in order to bill a DME MAC. Non-Medicare payers may allow billing for all services and supplies under a medical or other benefit.</p> <p>Report the appropriate EIP code and appropriate modifier(s) as documented in the medical record.</p> <p>Modifiers may be used to provide additional detail when billing for the EIP to the DME MAC.<sup>8</sup></p> <p>Note: Drug administration codes may get billed to the MAC and the E-codes may get billed separately to the DME MAC.</p> <p>Report any supplies as necessary.</p>

\*This is not an all-inclusive list of revenue codes; revenue codes will vary by institution. Revenue codes are only required on the CMS-1450.



# BLINCYTO® Billing Information Sheet



## Sample UB-04 (CMS-1450) Form: Hospital Outpatient Administration

1 Anytown Hospital 100 Main Street Anytown, Anystate 01010		2		3 a. PAT. CNTL. # b. MED. RES. #		4. TYPE OF BILL	
9 PATIENT NAME Smith, Jane		10 PATIENT ADDRESS 123 Main Street, Anytown, Anystate 12345		5 FED. TAX ID NO		6 STATEMENT COVERS PERIOD FROM THROUGH	
11 BIRTHDATE		12 SEX		13 DATE		14 ADMISSION 13 HR. 14 TYPE 15 SRC	
16 DHR		17 ST AT		18		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	
100		101		102		103	
104		105		106		107	
108		109		110		111	
112		113		114		115	
116		117		118		119	
120		121		122		123	
124		125		126		127	
128		129		130		131	
132		133		134		135	
136		137		138		139	
140		141		142		143	
144		145		146		147	
148		149		150		151	
152		153		154		155	
156		157		158		159	
160		161		162		163	
164		165		166		167	
168		169		170		171	
172		173		174		175	
176		177		178		179	
180		181		182		183	
184		185		186		187	
188		189		190		191	
192		193		194		195	
196		197		198		199	
200		201		202		203	
204		205		206		207	
208		209		210		211	
212		213		214		215	
216		217		218		219	
220		221		222		223	
224		225		226		227	
228		229		230		231	
232		233		234		235	
236		237		238		239	
240		241		242		243	
244		245		246		247	
248		249		250		251	
252		253		254		255	
256		257		258		259	
260		261		262		263	
264		265		266		267	
268		269		270		271	
272		273		274		275	
276		277		278		279	
280		281		282		283	
284		285		286		287	
288		289		290		291	
292		293		294		295	
296		297		298		299	
300		301		302		303	
304		305		306		307	
308		309		310		311	
312		313		314		315	
316		317		318		319	
320		321		322		323	
324		325		326		327	
328		329		330		331	
332		333		334		335	
336		337		338		339	
340		341		342		343	
344		345		346		347	
348		349		350		351	
352		353		354		355	
356		357		358		359	
360		361		362		363	
364		365		366		367	
368		369		370		371	
372		373		374		375	
376		377		378		379	
380		381		382		383	
384		385		386		387	
388		389		390		391	
392		393		394		395	
396		397		398		399	
400		401		402		403	
404		405		406		407	
408		409		410		411	
412		413		414		415	
416		417		418		419	
420		421		422		423	
424		425		426		427	
428		429		430		431	
432		433		434		435	
436		437		438		439	
440		441		442		443	
444		445		446		447	
448		449		450		451	
452		453		454		455	
456		457		458		459	
460		461		462		463	
464		465		466		467	
468		469		470		471	
472		473		474		475	
476		477		478		479	
480		481		482		483	
484		485		486		487	
488		489		490		491	
492		493		494		495	
496		497		498		499	
500		501		502		503	
504		505		506		507	
508		509		510		511	
512		513		514		515	
516		517		518		519	
520		521		522		523	
524		525		526		527	
528		529		530		531	
532		533		534		535	
536		537		538		539	
540		541		542		543	
544		545		546		547	
548		549		550		551	
552		553		554		555	
556		557		558		559	
560		561		562		563	
564		565		566		567	
568		569		570		571	
572		573		574		575	
576		577		578		579	
580		581		582		583	
584		585		586		587	
588		589		590		591	
592		593		594		595	
596		597		598		599	
600		601		602		603	
604		605		606		607	
608		609		610		611	
612		613		614		615	
616		617		618		619	
620		621		622		623	
624		625		626		627	
628		629		630		631	
632		633		634		635	
636		637		638		639	
640		641		642		643	
644		645		646		647	
648		649		650		651	
652		653		654		655	
656		657		658		659	
660		661		662		663	
664		665		666		667	
668		669		670		671	
672		673		674		675	
676		677		678		679	
680		681		682		683	
684		685		686		687	
688		689		690		691	
692		693		694		695	
696		697		698		699	
700		701		702		703	
704		705		706		707	
708		709		710		711	
712		713		714		715	
716		717		718		719	
720		721		722		723	
724		725		726		727	
728		729		730		731	
732		733		734		735	
736		737		738		739	
740		741		742		743	
744		745		746		747	
748		749		750		751	
752		753		754		755	
756		757		758		759	
760		761		762		763	
764		765		766		767	
768		769		770		771	
772		773		774		775	
776		777		778		779	
780		781		782		783	
784		785		786		787	
788		789		790		791	
792		793		794		795	
796		797		798		799	
800		801		802		803	
804		805		806		807	
808		809		810		811	
812		813		814		815	
816		817		818		819	
820		821		822		823	
824		825		826		827	
828		829		830		831	
832		833		834		835	
836		837		838		839	
840		841		842		843	
844		845		846		847	
848		849		850		851	
852		853		854		855	
856		857		858		859	
860		861		862		863	
864		865		866		867	
868		869		870		871	
872		873		874		875	
876		877		878		879	
880		881		882		883	
884		885		886		887	
888							

# BLINCYTO®

## Billing Information Sheet



### Physician Office - Multiple Payers (Medicare and Non-Medicare)

Item	Coding Information (ICD-10-CM <sup>7</sup> /CPT <sup>9</sup> /HCPCS <sup>8</sup> /NDC <sup>11</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM code(s) to describe the patient's condition.
<b>Procedure: Administration via CIVI using an EIP</b>	<b>96416</b> Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours) requiring use of a portable or implantable pump <b>OR</b> <b>96521</b> Refilling and maintenance of portable pump <b>OR</b> <b>G0498</b> Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion	CPT codes may be used to report the CIVI procedures associated with BLINCYTO® to the Part A/B MAC and non-Medicare payers. For Medicare patients, HCPCS code G0498 will replace CPT codes and HCPCS (96416, E0781, and 99211–99215) previously used to bill for prolonged infusion services when the CIVI is started in the physician office. It does not apply to BLINCYTO® when the CIVI is started in the inpatient setting or via home infusion. <sup>8,9,12</sup>  Some payers may not recognize G0498 and require itemization of specific items, instead. The healthcare provider should consult the payer or MAC to determine which code is most appropriate for administration of BLINCYTO®.
<b>Drug: BLINCYTO®</b>	<b>J9039</b> Injection, blinatumomab, 1 mcg <b>JW</b> Discarded drug/not administered to any patient <b>JZ</b> Zero drug amount discarded/not administered to any patient	Medicare requires use of the HCPCS code in the physician office setting <sup>18</sup> and has a maximum utilization of 210 units per date of service (based on prescribing information). <sup>19</sup> However, coding requirements may vary by payer.  Like many payers, Medicare requires the use of the modifier JW and JZ, which provides payment for the amount of drug or biologic discarded, as well as for the dose administered, up to the amount of the drug or biologic as indicated on the vial or label for an SDV. <sup>15</sup>  Note: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers.*
	<b>NDC: 55513016001</b> BLINCYTO® 35 mcg lyophilized powder, SDV IV solution stabilizer, 10 mL SDV	Some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When reporting the NDC on claims, use the 11-digit NDC in the 5-4-2 format. <sup>17</sup> Insert a leading zero in the appropriate section to complete the 5-4-2 digit format. Remove the dashes prior to entering the NDC on the claim form.
<b>DME: EIP and supplies</b>	<b>E0779</b> Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater <sup>22</sup> <b>E0781</b> Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient <sup>22</sup> <b>G0498</b> Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion <b>A4222</b> Infusion supplies for external drug infusion pump, per cassette or bag  <b>Modifiers for EIP</b> <b>-KD</b> Drug or biologic infused through DME <b>-RR</b> Rental <b>-KH</b> DMEPOS item, initial claim or first rental month <b>-KI</b> DMEPOS item, second or third rental months <b>-KJ</b> DMEPOS item, fourth to 15th rental months	Report the appropriate EIP code and appropriate modifier(s) as documented in the medical record.  Modifiers may be used to provide additional detail when billing for the EIP to the DME MAC. <sup>8</sup>  Note: Drug administration codes may get billed to the MAC and the E-codes may get billed separately to the DME MAC.  If the office bills the G-code to the MAC, the cost of the pump and supplies is bundled and should not be billed separately to the DME MAC. <sup>13</sup>  Report any supplies as necessary.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

# BLINCYTO® Billing Information Sheet



## Sample CMS-1500 Form: Physician Office Administration



### HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA <input type="checkbox"/>										PICA <input type="checkbox"/>	
1. MEDICARE <input type="checkbox"/> (Medicare#)	MEDICAID <input type="checkbox"/> (Medicaid#)	TRICARE <input type="checkbox"/> (ID#/DoD#)	CHAMPVA <input type="checkbox"/> (MemberID#)	GROUP HEALTH PLAN <input type="checkbox"/> (ID#)	FECA BLK LUNG <input type="checkbox"/> (ID#)	OTHER <input type="checkbox"/> (ID#)	1a. INSURED'S I.D. NUMBER (For Program In Item 1)				
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)				3. PATIENT'S BIRTH DATE MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		4. INSURED'S NAME (Last Name, First Name, Middle Initial)			
5. PATIENT'S ADDRESS (No., Street)				6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>		7. INSURED'S ADDRESS (No., Street)					
CITY		STATE		CITY		STATE					
ZIP CODE		TELEPHONE (Include Area Code)		ZIP CODE		TELEPHONE (Include Area Code)					
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)				10. IS PATIENT'S CONDITION RELATED TO:		11. INSURED'S POLICY GROUP OR FECA NUMBER					
a. OTHER INSURED'S POLICY OR GROUP NUMBER		a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO		a. INSURED'S DATE OF BIRTH MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>					
b. RESERVED FOR NUCC USE		b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO		b. OTHER CLAIM ID (Designated by NUCC)							
c. RESERVED FOR NUCC USE		c. OTHER ACCIDENT <input type="checkbox"/> YES <input type="checkbox"/> NO									
d. INSURANCE PLAN NAME OR PROGRAM NAME				10d. CLAIM CODE							

**NDC (BOX 24A SHADED AREA):** When reporting BLINCYTO®, some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When required by the payer, report the NDC qualifier "N4," indicating that an NDC follows, and the NDC in the 11-digit format. The unit of measure can also be reported, 3 spaces after the NDC, as UNX (X = the number of vials). Verify the payer-specific claim submission requirements

**DIAGNOSIS (BOX 21):** Enter the appropriate diagnosis code; eg, ICD-10-CM:

- **Z51.12** Encounter for antineoplastic immunotherapy **AND**
- **C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**
- **C91.01** Acute lymphoblastic leukemia, in remission **OR**
- **C91.02** Acute lymphoblastic leukemia, in relapse

Final codes depend on medical record documentation

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A–L) that corresponds to the diagnosis in Box 21

**UNITS (Box 24G):** Report units of service for both units administered and amount of discarded drug. BLINCYTO® dose reported as 1 unit per mcg. Report 1 unit for initiation of CIVI via EIP or refill of EIP

**PLACE OF SERVICE (Box 24B):** Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg, • **11** Physician office

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):** Enter the appropriate administration procedure. Use the CPT code representing the procedure performed, such as initiation OR refill; eg, **96416** Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump **OR** **96521** Refilling and maintenance of portable pump **OR** **G0498** Chemotherapy administration, IV infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (eg, home, domiciliary, rest home, or assisted living) using a portable pump provided by the office/clinic; includes follow-up office/clinic visit at the conclusion of the infusion

**JW/JZ Discard Modifier:** JW or JZ modifier required for Medicare Part B claims for drugs in single-use containers

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO®

## Billing Information Sheet



### Home Infusion - Multiple Payers (Medicare and Non-Medicare)

Item	Coding Information (ICD-10-CM <sup>7</sup> /CPT <sup>9</sup> /HCPCS <sup>8</sup> /NDC <sup>11</sup> )	Notes
<b>Diagnosis: Encounter for drug therapy and ALL</b>	<b>Z51.12</b> Encounter for antineoplastic immunotherapy <b>AND</b> <b>C91.00</b> Acute lymphoblastic leukemia not having achieved remission <b>OR</b> <b>C91.01</b> Acute lymphoblastic leukemia, in remission <b>OR</b> <b>C91.02</b> Acute lymphoblastic leukemia, in relapse	Report the appropriate ICD-10-CM code(s) to describe the patient's condition.
<b>Procedure: Administration via CIVI using an EIP</b>	<b>G0090</b> Professional services, initial visit, for the administration of intravenous chemotherapy or other highly complex infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes <sup>1</sup> <b>G0070</b> Professional services for the administration of intravenous chemotherapy or other intravenous highly complex drug or biological infusion for each infusion drug administration calendar day in the individual's home, each 15 minutes <sup>1</sup> <b>99601</b> Home infusion/specialty drug administration, per visit (up to 2 hours) <b>99602</b> Each additional hour <b>S9329</b> Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9330</b> Home infusion therapy, continuous (24 hours or more) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9338</b> Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <b>S9379</b> Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	Home infusion therapy services for Medicare beneficiaries receiving BLINCYTO® should be billed using G0090 for an initial visit and G0070 for subsequent visits. Some or all Medicare contractors may reject chemotherapy CPT codes with the availability of G0070 and G0090. These services must be reported to the A/B MAC, and are reimbursed by Medicare at rates set by the Medicare Physician Fee Schedule. They are billed and paid separately from the external infusion pump and drug, which are billed to the DME MAC and reimbursed under the DMEPOS Fee Schedule. Medicare requires that a claim for BLINCYTO® be billed no more than 30 days prior to the visit. Otherwise, payment for the home infusion therapy service will be denied. <sup>1</sup> These services may be covered by Medicaid, commercial plans, or Medicare Advantage plans. <sup>20</sup> CPT codes 99601 and 99602, as well as certain S-codes, may be used to report home infusion therapy services to other payer types other than FFS Medicare. Please note that FFS Medicare does not recognize S-codes, although other payers might. <sup>20</sup>
<b>Drug: BLINCYTO®</b>	<b>J9039</b> Injection, blinatumomab, 1 mcg <b>JW</b> Discarded drug/not administered to any patient <b>JZ</b> Zero drug amount discarded/not administered to any patient	Medicare requires that claims for BLINCYTO®, the pump, and supplies be sent to the DME MACs. Claims for home infusion therapy services must now be submitted separately and are processed by Part A/B MACs. <sup>1</sup> Medicare sets maximum utilization at 875 units of service (UOS), which is equivalent to 25 vials per month in this site of care. <sup>21</sup> Many payers require the use of the modifier JW and JZ, which provides payment for the amount of drug or biologic discarded, as well as for the dose administered, up to the amount of the drug or biologic as indicated on the vial or label for an SDV. <sup>15</sup> Note: Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use vials and containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers.*
	<b>NDC: 55513016001</b> BLINCYTO® 35 mcg lyophilized powder, SDV IV solution stabilizer, 10 mL SDV	Some payers (eg, Medicaid) may require listing the NDC in addition to the HCPCS J-code. When reporting the NDC on claims, use the 11-digit NDC in the 5-4-2 format. <sup>17</sup> Insert a leading zero in the appropriate section to complete the 5-4-2 digit format. Remove the dashes prior to entering the NDC on the claim form.
<b>DME: EIP and supplies</b>	<b>E0779</b> Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater <sup>22</sup> <b>E0781</b> Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient <sup>22</sup> <b>A4222</b> Infusion supplies for external drug infusion pump, per cassette or bag <b>Modifiers for EIP</b> <b>-KD</b> Drug or biologic infused through DME <b>-RR</b> Rental <b>-KH</b> DMEPOS item, initial claim or first rental month <b>-KI</b> DMEPOS item, second or third rental months <b>-KJ</b> DMEPOS item, fourth to 15th rental months	Report the appropriate EIP code and appropriate modifier(s) as documented in the medical record. Modifiers may be used to provide additional detail when billing for the EIP to the DME MAC. <sup>8</sup> Report any supplies as necessary.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO® Billing Information Sheet



## Sample CMS-1500 Form: Medicare DME MAC for BLINCYTO®, Pump, and Related Supplies by DME Supplier

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

CARRIER

PATIENT AND INSURED INFORMATION

PHYSICIAN

PICA  PICA

1. MEDICARE  MEDICAID  TRICARE  CHAMPVA  GROUP HEALTH PLAN  FECA/BLK LUNG  OTHER

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX M  F

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. INSURED'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED: Self  Spouse  Child  Other

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. RESERVED FOR NUCC USE

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES  NO  If yes, complete items 9, 9a, and 9d.

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim to the payer, either to myself or to the party who accepts assignment.

14. DATE \_\_\_\_\_ SIGNED \_\_\_\_\_

In 2021, Medicare requires drugs furnished as an item of DME and home infusion therapy services to be billed on separate claims. This claim illustrates sample billing for the drug and DME supplies for a Medicare patient. See the sample claim form on page 11 for guidance on billing for home infusion therapy services for a Medicare beneficiary

**NDC (BOX 24A SHADED AREA):** When required by the payer, report the NDC qualifier "N4," indicating that an NDC follows, and the NDC in the 11-digit format. The unit of measure can also be reported, 3 spaces after the NDC, as UNX (X = the number of vials)

**DIAGNOSIS (BOX 21):**  
Enter the appropriate diagnosis code; eg, ICD-10-CM:  
**Z51.12** Encounter for antineoplastic immunotherapy **AND**  
**C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**  
**C91.01** Acute lymphoblastic leukemia, in remission **OR**  
**C91.02** Acute lymphoblastic leukemia, in relapse  
Final codes depend on medical record documentation

**UNITS (Box 24G):**  
Report units of service for both units administered and amount of discarded drug. BLINCYTO® dose reported as 1 unit per mcg. Report 1 unit each for EIP and other supplies

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**PLACE OF SERVICE (Box 24B):**  
Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg,  
• 12 Home

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):**  
Enter the appropriate CPT/HCPCS codes and modifiers; eg,  
• Drug: **J9039** for BLINCYTO®  
**JW/JZ Discard Modifier:** JW or JZ modifier required for Medicare DME external infusion pump claims including infused drugs in single-use containers  
• IV Pump: **E0781** Ambulatory infusion pump  
• **A4222** Infusion supplies for external drug infusion pump, per cassette or infusion option  
Other codes may be appropriate. Check with individual Medicare DME MACs for detailed guidance

1	A. DATE(S) OF SERVICE		B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES		E. DIAGNOSIS POINTER	F. \$ CHARGES		G. DAYS OR UNITS	H. EPCS PLAN	I. QUAL
	From MM/DD/YY	To MM/DD/YY			CPT/HCPCS	MODIFIER						
1	MM/DD/YY	MM/DD/YY	12		J9039		A B	XXX	XX	X		NPI
2	MM/DD/YY	MM/DD/YY	12		J9039	JW	A B	XXX	XX	X		NPI
3	MM/DD/YY	MM/DD/YY	12		E0781	RR KH	A B	XXX	XX	1		NPI
4	MM/DD/YY	MM/DD/YY	12		A4222		A B					
5												


This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO® Billing Information Sheet



## Sample CMS-1500 form: Medicare A/B MAC for Home Infusion Therapy Services by Home Infusion Therapy Supplier



### HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

CARRIER

PICA  PICA

1. MEDICARE <small>(Medicare#)</small>	MEDICAID <small>(Medicaid#)</small>	TRICARE <small>(ID#/DoD#)</small>	CHAMPVA <small>(Member ID#)</small>	GROUP HEALTH PLAN <small>(ID#)</small>	FECA BLK (LUNG) <small>(ID#)</small>	OTHER <small>(ID#)</small>	1a. INSURED'S I.D. NUMBER <small>(For Program In Item 1)</small>
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)							4. INSURED'S NAME (Last Name, First Name, Middle Initial)
3. PATIENT'S BIRTH DATE MM DD YY							7. INSURED'S ADDRESS (No., Street)
SEX M <input type="checkbox"/> F <input type="checkbox"/>							8. RESERVED FOR NUCC USE
8. RESERVED FOR NUCC USE							CITY
STATE							STATE
10. IS PATIENT'S CONDITION RELATED TO:							11. INSURED'S POLICY GROUP OR FECA NUMBER
a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO							a. INSURED'S DATE OF BIRTH MM DD YY
b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO							SEX M <input type="checkbox"/> F <input type="checkbox"/>
c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO							b. OTHER CLAIM ID (Designated by NUCC)
10d. CLAIM CODES (Designated by NUCC)							c. INSURANCE PLAN NAME OR PROGRAM NAME
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE. I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.							d. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO <i>If yes, complete items 9, 9a, and 9d.</i>
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY							13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE. I authorize payment of medical benefits to the undersigned physician or supplier for services described below.
15. OTHER DATE							16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE							
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)							
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY. Relate A-L to 24E.							
A. <b>Z51.12</b> B. <b>C91.02</b>							
24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. C. D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS (OR UNITS) H. I. J. K. L.							
1 MM DD YY MM DD YY 12 G0090 A B XXX XX X NPI							
2 MM DD YY MM DD YY 12 J9039 A B 0 00 X NPI							
3							
4							
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)							
32. SIGNATURE OF PATIENT OR AUTHORIZED REPRESENTATIVE							

NUCC Instruction Manual available at: [www.nucc.org](http://www.nucc.org)

In 2021, Medicare requires separate claims for home infusion therapy services and for drugs furnished as items of DME in the home infusion setting. This sample claim shows an example for billing home infusion therapy services for a Medicare patient. See the sample claim form on page 10 for guidance on billing for drugs furnished as an item of DME for a Medicare beneficiary

**DIAGNOSIS (BOX 21):**  
Enter the appropriate diagnosis code; eg, ICD-10-CM:  
**Z51.12** Encounter for antineoplastic immunotherapy **AND**  
**C91.00** Acute lymphoblastic leukemia not having achieved remission **OR**  
**C91.01** Acute lymphoblastic leukemia, in remission **OR**  
**C91.02** Acute lymphoblastic leukemia, in relapse  
Final codes depend on medical record documentation

**UNITS (Box 24G):**  
Report units of service for the administration of BLINCYTO®, reported as 1 unit per 15 minutes of time of IV infusion

**PLACE OF SERVICE (Box 24B):**  
Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg,  
• 12 Home

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):**  
Enter the appropriate CPT/HCPCS codes and modifiers; eg,  
• IV Infusion: **G0090** for IV infusion of BLINCYTO®, initial visit  
• Drug: **J9039** is added to identify BLINCYTO® as the drug related to the administration service; List a zero charge to indicate that no reimbursement for the drug is expected  
Other codes may be appropriate. Check with individual Medicare A/B MAC for detailed guidance

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.


Please see Important Safety Information for BLINCYTO® on pages 18-19.

11

# BLINCYTO® Billing Information Sheet



## Sample CMS-1500 Form: Non-Medicare Payer by Home Infusion Provider



### HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA    PICA

<input type="checkbox"/> 1. MEDICARE <small>(Medicare#)</small>	<input type="checkbox"/> MEDICAID <small>(Medicaid#)</small>	<input type="checkbox"/> TRICARE <small>(ID#/DoD#)</small>	<input type="checkbox"/> CHAMPVA <small>(Member ID#)</small>	<input type="checkbox"/> GROUP HEALTH PLAN <small>(ID#)</small>	<input type="checkbox"/> FECA BLK/LUNG <small>(ID#)</small>	<input type="checkbox"/> OTHER <small>(ID#)</small>	1a. INSURED'S I.D. NUMBER <small>(For Program in Item 1)</small>				
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)				3. PATIENT'S BIRTH DATE MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		4. INSURED'S NAME (Last Name, First Name, Middle Initial)			
5. PATIENT'S ADDRESS (No., Street)				6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>		7. INSURED'S ADDRESS (No., Street)					
CITY				STATE		CITY					
ZIP CODE				TELEPHONE (Include Area Code) ( )		ZIP CODE					
TELEPHONE (Include Area Code) ( )				8. RESERVED FOR NUCC USE		TELEPHONE (Include Area Code) ( )					
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)				10. IS PATIENT'S CONDITION RELATED TO:		11. INSURED'S POLICY GROUP OR FECA NUMBER					
a. OTHER INSURED'S POLICY OR GROUP NUMBER				a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO		a. INSURED'S DATE OF BIRTH MM DD YY					
b. RESERVED FOR NUCC USE				b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO		SEX M <input type="checkbox"/> F <input type="checkbox"/>					
c. RESERVED FOR NUCC USE				c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO		b. OTHER CLAIM ID (Designated by NUCC)					
d. INSURANCE PLAN NAME OR PROGRAM NAME				10d. CLAIM CODES (Designated by NUCC)		c. INSURANCE PLAN NAME OR PROGRAM NAME					
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits, either to myself or to the party who accepts assignment.				13. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO <i>If yes, complete items 9, 9a, and 9d.</i>		d. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO <i>If yes, complete items 9, 9a, and 9d.</i>					
13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize payment of medical benefits to the undersigned physician or supplier for services described below.				DATE		SIGNED					
16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION				DATE		DATE					
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below.				A. Z51.12		B. C91.02		C.		D.	
24. A. DATE(S) OF SERVICE				B. PLACE OF SERVICE		C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES		E. DIAGNOSIS	
From To				MM DD YY MM DD YY		12		J9039		A B	
1. N45513016001 UNX				MM DD YY MM DD YY		12		J9039 JW		XXX XX X	
2. N45513016001 UNX				MM DD YY MM DD YY		12		99601		XXX XX X	
3. N45513016001 UNX				MM DD YY MM DD YY		12		A4222		XXX XX X	
4. N45513016001 UNX				MM DD YY MM DD YY		12		A4222		XXX XX X	

**NDC (BOX 24A SHADED AREA):** When required by the payer, report the NDC qualifier "N4," indicating that an NDC follows, and the NDC in the 11-digit format. The unit of measure can also be reported, 3 spaces after the NDC, as UNX (X = the number of vials). Verify the payer-specific claim submission requirements

**DIAGNOSIS (BOX 21):** Enter the appropriate diagnosis code; eg, ICD-10-CM:

- Z51.12 Encounter for antineoplastic immunotherapy AND
- C91.00 Acute lymphoblastic leukemia not having achieved remission OR
- C91.01 Acute lymphoblastic leukemia, in remission OR
- C91.02 Acute lymphoblastic leukemia, in relapse

Final codes depend on medical record documentation

**DIAGNOSIS POINTER (Box 24E):** Enter the letter (A-L) that corresponds to the diagnosis in Box 21

**UNITS (Box 24G):** Report units of service for both units of drug administered and amount of discarded drug. BLINCYTO® dose reported with 1 unit per 1mcg

**PLACE OF SERVICE (Box 24B):** Enter the appropriate 2-digit place of service code that corresponds to the location where services are rendered; eg, • 12 Home

**PROCEDURES/SERVICES/SUPPLIES (Box 24D):** Enter the appropriate CPT/HCPCS codes and modifiers; eg,

- Drug: J9039 for BLINCYTO®
- 99601 Home infusion/specialty drug administration, per visit (up to 2 hours)
- A4222 Infusion supplies for external drug infusion pump, per cassette or infusion option

Other codes may be appropriate. Check with individual payers for detailed guidance  
NOTE: Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

12

**BLINCYTO® Dosing Options<sup>11</sup>**

Dosing option	Dose per vial X number of SDVs*	Number of billing units
24-hour	35 mcg X 1 vial	35
48-hour	35 mcg X 1-2 vials	35-70
7-day	35 mcg X 4-6 vials	140-210

\*Number of SDVs depends on dose, infusion duration, and patient's weight.<sup>11</sup>

**Key Considerations for the BLINCYTO® 7-day Infusion Option (7-DIO)**



Minor variations are expected in coding, billing, and claims filing for the BLINCYTO® 7-DIO.<sup>20</sup>



The 7-DIO requires 6 vials of BLINCYTO® and 1 vial of IV Solution Stabilizer for patients ≥ 45 kg. For patients weighing less than 45 kg, 4 to 5 vials are required. The safety of the administration of BLINCYTO® at a BSA of less than 0.4 m<sup>2</sup> has not been established.<sup>11</sup> Refer to the Prescribing Information for details on handling and preparation.



If the units field on a claim form cannot accommodate more than 99 units, utilize multiple lines to capture all units (eg, 99+98+13). Payers may require separate reporting of drug units administered and discarded.<sup>20</sup>



Less frequent claim submissions are expected with utilization of the 7-DIO. Typically the entire 7-DIO can be billed on the day of administration/refill. However, be sure to refer to payer guidelines for maximum daily quantity limits. Apply the appropriate dates of service as needed.<sup>20</sup>



If the 7-DIO is interrupted mid-treatment, refer to payer guidelines for reporting and documentation in these cases. If full reimbursement is withheld by the payer, refer to Amgen's Product Return Policy for assistance.




Existing codes and modifiers are adequate to report BLINCYTO® and its related services; however, payer requirements may vary with respect to:<sup>20</sup>

- The entities that can bill for DME and the associated supplies
- The number of units billed for BLINCYTO® J9039 (HCPCS units vs number of vials)
- Covered diagnosis codes
- Covered nursing services (eg, infusion services at patient's home)
- Drug claim submission options (eg, 1 or more dates of service on claims)
- Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.



# UNDERSTANDING EXAMPLES OF



## REIMBURSEMENT ACROSS SITES OF CARE

A BLINCYTO® patient transitions through multiple sites of care. This guide shows how major payers in the United States (commercial plans, Medicare, and Medicaid) offer coverage in each setting and reimburse for each component of care:



**Drug**



**Pump and Supplies**



**Hospitalization**



**Professional Services (ie, drug administration)**

### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION

**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**


- Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.
- Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.

Please see additional Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO® (blinatumomab) Reimbursement Process

Coverage of BLINCYTO® and its administration is required in all these sites of care to avoid interruption in treatment.

## Patient Flow







The scenarios depicted above illustrate the most common ones for accessing BLINCYTO® via the buy-and-bill acquisition process, where the entity that acquires the product also administers it to the patient.

BLINCYTO® can also be acquired via a specialty pharmacy provider, including:




- Third-party specialty pharmacies that contract with a payer to supply specialty products covered under the medical benefit
- Specialty pharmacies owned by hospitals, physician offices, ambulatory infusion clinics, and/or home infusion companies that may also administer the medication

# BLINCYTO® Reimbursement Across Transitions in Site of Care

BLINCYTO®-eligible patients need coverage for the following: Drug + Pump + Hospitalization + Administration

Inpatient Hospital			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	MS-DRG-based or global payment; typically includes BLINCYTO® <sup>23</sup>  Reimbursement varies by contracts between providers and payers	MS-DRG payment includes BLINCYTO® <sup>24</sup>  Covered under Medicare Part A benefit <sup>25</sup>	APR-DRG-based payment; typically includes BLINCYTO® <sup>27</sup>  Reimbursement varies by state; may follow Medicare allowable amounts
<b>Pump and Supplies</b> 	Some hospitals, in their contracts with managed care organizations, may negotiate a “carve out” benefit for drugs such as BLINCYTO® <ul style="list-style-type: none"> <li>• May allow separate payment of such drugs outside of the bundled payment for inpatient services</li> </ul>	Hospital may be eligible for outlier payments if cost of admission exceeds certain threshold	
<b>Hospitalization</b> 		Reimbursement varies for the 11 IPPS-Exempt Cancer Hospitals <sup>26</sup>	
<b>Professional Services</b> 	Physician services may be covered separately outside of the bundled payment	Physician services may be covered and reimbursed according to the MPFS under Medicare Part B benefit	Physician services may be covered and paid outside of the bundled payment




Key: APR-DRG – All Patient-Refined Diagnosis Related Groups; FFS – fee-for-service; IPPS – Inpatient Prospective Payment System; MPFS – Medicare Physician Fee Schedule; MS-DRG – Medicare Severity Diagnosis-Related Group.

Outpatient Hospital			
Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
<b>BLINCYTO®</b> 	Reimbursed based on contracted rates; methodology varies Examples: <sup>28</sup> <ul style="list-style-type: none"> <li>• ASP + X%</li> <li>• WAC + X%</li> <li>• AWP – X%</li> </ul> May need prior authorization	Covered under Medicare Part B benefit  Typically reimbursed based on ASP + 6% when administered in a 340B hospital setting (with 2% sequestration reduction) <sup>29,30</sup>  MUE cap of 210 units (approx. 6 vials) per date of service applies <sup>31,8</sup>	Reimbursement may be similar to Medicare  OR State-defined limit (eg, California uses a federal upper limit) <sup>32</sup>  May need prior authorization
<b>Pump and Supplies</b> 	Reimbursement is bundled into the payment for the infusion service	Covered under Medicare Part B benefit  Reimbursement is bundled into the payment for the infusion service	Reimbursed based on fee schedule or bundled into the payment for the infusion service  Rates vary by state
<b>Professional Services</b> 	Reimbursed based on contracted rate	Reimbursed based on the Medicare OPSS	

Key: ASP – average sales price; AWP – average wholesale price; FFS – fee-for-service; MUE – medically unlikely edit; OPSS – Outpatient Prospective Payment System; WAC – wholesale acquisition cost.




Note: The information here describes coverage and payment for BLINCYTO® under FFS Medicare and FFS Medicaid. Coverage and payment for patients enrolled in Medicare Advantage and/or Medicaid managed care organizations varies widely and is often similar to commercial insurance.

## Physician Office

Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
 <p><b>BLINCYTO®</b></p> <p>Reimbursed based on contracted rates; methodology varies Examples:<sup>28</sup></p> <ul style="list-style-type: none"> <li>• ASP + X%</li> <li>• WAC + X%</li> <li>• AWP – X%</li> </ul> <p>May need prior authorization</p>	<p>Reimbursed based on contracted rates; methodology varies Examples:<sup>28</sup></p> <ul style="list-style-type: none"> <li>• ASP + X%</li> <li>• WAC + X%</li> <li>• AWP – X%</li> </ul> <p>May need prior authorization</p>	<p>Covered under Medicare Part B benefit</p> <p>Typically reimbursed based on ASP + 6% (with 2% sequestration reduction)<sup>30,33</sup></p> <p>MUE cap of 210 units (approx. 6 vials) per date of service applies<sup>8,19</sup></p>	<p>Reimbursement may be similar to Medicare</p> <p>OR</p> <p>State-defined limit (eg, California uses a federal upper limit)<sup>32</sup></p> <p>May need prior authorization</p>
 <p><b>Pump and Supplies</b></p> <p>Reimbursed based on contracted rate and bundled into payment for the infusion service</p>	<p>Reimbursed based on contracted rate and bundled into payment for the infusion service</p>	<p>Covered under Medicare Part B benefit</p> <p>Reimbursement is bundled into the payment for the infusion service</p>	<p>Typically reimbursed based on fee schedule or bundled into the payment for the infusion service</p> <p>Rates vary by state</p>
 <p><b>Professional Services</b></p> <p>Reimbursed based on contracted rate</p>	<p>Reimbursed based on contracted rate</p>	<p>Reimbursed based on the MPFS</p>	

Key: ASP – average sales price; AWP – average wholesale price; FFS – fee-for-service; MPFS – Medicare Physician Fee Schedule; MUE – medically unlikely edit; WAC – wholesale acquisition cost.

## Home Infusion

Components of BLINCYTO® Care	Commercially Insured Patients	FFS Medicare Patients	FFS Medicaid Patients
 <p><b>BLINCYTO®</b></p> <p>Reimbursed based on contracted rates; methodology varies Examples:<sup>28</sup></p> <ul style="list-style-type: none"> <li>• ASP + X%</li> <li>• WAC + X%</li> <li>• AWP – X%</li> </ul> <p>May need prior authorization</p>	<p>Reimbursed based on contracted rates; methodology varies Examples:<sup>28</sup></p> <ul style="list-style-type: none"> <li>• ASP + X%</li> <li>• WAC + X%</li> <li>• AWP – X%</li> </ul> <p>May need prior authorization</p>	<p>Covered under Medicare Part B as long as it is supplied in a covered external infusion pump and the IV is initiated in home infusion setting<sup>34</sup></p> <p>Typically reimbursed based on ASP + 6% (with 2% sequestration reduction)<sup>30,33</sup></p> <p>Billing cap of 25 vials per month applies<sup>21</sup></p>	<p>Reimbursement may be similar to Medicare</p> <p>OR</p> <p>State-defined limit (eg, California uses a federal upper limit)<sup>37</sup></p> <p>May need prior authorization</p>
 <p><b>Pump and Supplies</b></p> <p>Reimbursed based on contracted rate</p>	<p>Reimbursed based on contracted rate</p>	<p>Covered under Medicare Part B benefit</p> <p>Reimbursed as part of the Medicare DMEPOS Fee Schedule<sup>35</sup></p>	<p>Typically reimbursed based on fee schedule</p> <p>Rates vary by state</p>
 <p><b>Professional Services</b></p> <p>Reimbursed based on contracted rate</p>	<p>Reimbursed based on contracted rate</p>	<p>Covered under Part B</p> <p>Reimbursed under the home infusion therapy services benefit in 15-minute increments for applicable providers<sup>36</sup></p>	

Key: ASP – average sales price; AWP – average wholesale price; DMEPOS – Durable Medical Equipment Prosthetics, Orthotics, and Supplies; FFS – fee-for-service; WAC – wholesale acquisition cost.

Note: Medicare home infusion benefit is distinct and separate from the Medicare home health benefit.

Please see Important Safety Information for BLINCYTO® on pages 18-19.

# BLINCYTO®

## Indications and Important Safety Information



### INDICATIONS

BLINCYTO® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with:

- Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy
- Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission
- Relapsed or refractory disease

### IMPORTANT SAFETY INFORMATION

**WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- **Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® and treat with corticosteroids as recommended.**
- **Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening or fatal, occurred in patients receiving BLINCYTO®. Interrupt or discontinue BLINCYTO® as recommended.**

### Contraindications

BLINCYTO® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.

### Warnings and Precautions

- **Cytokine Release Syndrome (CRS):** CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO®. The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin, and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO, CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO® until CRS resolves. Discontinue BLINCYTO® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS.

- **Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome:** BLINCYTO® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO® treatment. The most common ( $\geq 10\%$ ) manifestations of neurologic toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO®, but some resulted in treatment discontinuation.

The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO® therapy.

Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities.

- **Infections:** Approximately 25% of patients receiving BLINCYTO® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO® as needed.
- **Tumor Lysis Syndrome (TLS),** which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment non-toxic cytoreduction and on-treatment hydration, should be used during BLINCYTO® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO® as needed to manage these events.
- **Neutropenia and Febrile Neutropenia,** including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO® infusion and interrupt BLINCYTO® if prolonged neutropenia occurs.
- **Effects on Ability to Drive and Use Machines:** Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO® is being administered.
- **Elevated Liver Enzymes:** Transient elevations in liver enzymes have been associated with BLINCYTO® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO®, although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than

### IMPORTANT SAFETY INFORMATION (continued)

1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO<sup>®</sup> treatment. BLINCYTO<sup>®</sup> treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN.

- **Pancreatitis:** Fatal pancreatitis has been reported in patients receiving BLINCYTO<sup>®</sup> in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO<sup>®</sup> and dexamethasone as needed.
- **Leukoencephalopathy:** Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO<sup>®</sup>, especially in patients previously treated with cranial irradiation and antileukemic chemotherapy.
- **Preparation and administration** errors have occurred with BLINCYTO<sup>®</sup> treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose).
- **Immunization:** Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO<sup>®</sup> treatment, during treatment, and until immune recovery following last cycle of BLINCYTO<sup>®</sup>.
- **Benzyl Alcohol Toxicity in Neonates:** Serious adverse reactions, including fatal reactions and the “gasping syndrome,” have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

Use the preservative-free preparations of BLINCYTO<sup>®</sup> where possible in neonates. When prescribing BLINCYTO<sup>®</sup> (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO<sup>®</sup> (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway.

Monitor neonatal patients receiving BLINCYTO<sup>®</sup> (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO<sup>®</sup> 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL.

- **Embryo-Fetal Toxicity:** Based on its mechanism of action, BLINCYTO<sup>®</sup> may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO<sup>®</sup> and for 48 hours after the last dose.

### Adverse Reactions

- The safety of BLINCYTO<sup>®</sup> in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO<sup>®</sup> in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.

### Dosage and Administration Guidelines

- BLINCYTO<sup>®</sup> is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm.
- It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose).

Please see BLINCYTO<sup>®</sup> [full Prescribing Information](#), including **BOXED WARNINGS**.

**Please note:** The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for their own patients and procedures. In no way should the information provided in this document be considered a guarantee of coverage or reimbursement for any product or service.

## We're right here, right when you need us



### HCP Support Center

Our Amgen SupportPlus Representatives can assist with issues around patient coverage, prior authorizations, co-pay programs, and more.

### Benefits Verification

- Verify patient's insurance plan coverage details

### Prior Authorization Requirements

- Provide payer-specific prior authorization forms

### Amgen SupportPlus Customer Portal

- A tool for managing patient benefits verification and more
- Submit, store, and retrieve benefit verifications electronically



### Amgen® Patient Navigator

A single point of contact to help answer questions about access and reimbursement, navigating treatment logistics, and to provide supplemental resources as your patients transition from hospital to outpatient care.

### Amgen Patient Navigators can help with:

- Benefits verification and understanding coverage
- Prior authorization process
- Reimbursement and access resources

The Amgen Patient Navigator is not part of a patient's treatment team and does not provide medical advice or case management services. The Amgen Patient Navigator does not administer Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Visit [AmgenTherapyLocator.com](http://AmgenTherapyLocator.com) to locate alternative sites where BLINCYTO® can be administered to your patients\*

\*The information on this website is reported by independent third-party sites that administer or deliver treatment to patients. It is not comprehensive of all sites that handle the therapies listed, and Amgen does not confirm accuracy or otherwise endorse any of these sites.

Note: Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. This information is not a guarantee of coverage or reimbursement.

1234 5678 9100 0123

RxBIN: XXXXXX MEMBER ID: XXXXXXXXXX  
PCN: XX GROUP: XXXXXXXXXX

Questions? Call (866) 264-2778

The Amgen SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.

- Pay as little as **\$0 out-of-pocket** for each dose or cycle
- Can be applied to deductible, co-insurance, and co-payment†
- No income eligibility requirement

†Eligibility criteria and program maximums apply. See [AmgenSupportPlus.com/copy](http://AmgenSupportPlus.com/copy) for full Terms and Conditions.

Encourage your patients with private or commercial insurance to check eligibility and enroll at [AmgenSupportPlus.com/copy](http://AmgenSupportPlus.com/copy)

### What if my patient doesn't have private or commercial insurance?

Amgen SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help.†

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

**References:** 1. MLN Matters. Billing for home infusion therapy services on or after January 1, 2021. <https://www.cms.gov/files/document/mml1880.pdf>. Accessed June 12, 2024. 2. CMS. Medicare Claims Processing Manual Chapter 20. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c20.pdf>. Accessed June 12, 2024. 3. CMS. CY 2024 Medicare Physician Fee Schedule Rule, Available at: <https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2024-medicare-physician-fee-schedule-final-rule>; Accessed June 3, 2024. 4. CMS. 2% Payment Adjustment Sequestration Changes, December 16, 2021, available at <https://www.cms.gov/outreach-and-education/outreach/factsheets/prop-part-prog-provider-partnership-email-archive/2021-12-16-minc>. Accessed June 12, 2024. 5. Value Healthcare Services. Understanding Hospital Revenue Codes. <http://valuehealthcareservices.com/education/understanding-hospital-revenue-codes/>. Accessed June 12, 2024. 6. CMS. Medicare Claims Processing Manual Chapter 3. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c03.pdf>. Accessed June 12, 2024. 7. Centers for Disease Control and Prevention. ICD-10-CM FY 2022 List of Codes and Descriptions. [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD10CM/2022/](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/). Accessed June 12, 2024. 8. Centers for Medicare & Medicaid Services. July 2021 Alpha-Numeric HCPCS File. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>. Page last modified July 23, 2021. Accessed July 5, 2023. 9. American Medical Association (AMA). *CPT 2021 Professional Edition*. AMA; 2020. 10. CMS. 2021 ICD-10-PCS Codes and Tables Index. <https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs>. Accessed June 12, 2024. 11. BLINCYTO® (blinatumomab) prescribing information. Amgen. 12. CMS. CMS Manual System. Pub 100-04. <https://www.cms.gov/Regulations-and-Guidance/Transmittals/2017Downloads/R3728CP.pdf>. Accessed June 12, 2024. 13. Association of Community Cancer Centers (ACCC). Oncology Reimbursement Coding Update 2017. <https://www.accc-cancer.org/publications/pdf/Oncology-Reimbursement-Coding-Update-2017.pdf>. Accessed June 12, 2024. 14. CMS. Facility Outpatient Hospital Services MUE Table - Effective-01-01-2021-Replacement-Posted September 3, 2021. <https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/MUE>. Accessed June 12, 2024. 15. 2023 Physician Fee Schedule Final Rule (87 FR 69710 - 69734, November 13, 2022); 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule (87 FR 71988, 72082 - 72083, November 23, 2022); Medicare Program, Discarded Drugs and Biologicals - JW Modifier and JZ Modifier Policy, Frequently Asked Questions, available at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>. Accessed June 12, 2024. 16. CMS, Revised Part B Inflation Rebate Guidance: Use of the 340B Modifier, Available at: <https://www.cms.gov/files/document/revised-part-b-inflation-rebate-340b-modifier-guidance.pdf>; Accessed June 3, 2024. 17. Department of Health and Human Services. Health Insurance Reform: Standards for Electronic Transactions. Office of the Secretary, HHS. Final rule. *Fed Regist.* 2000;65(160):50312-50372. 18. CMS. Medicare Claims Processing Manual Chapter 23. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c23.pdf>. Accessed June 12, 2024. 19. CMS. Practitioner Services MUE Table - Effective-04-01-2021-Posted March 2, 2021. <http://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/MUE>. Accessed July 5, 2023. 20. Data on file, Amgen; [Xcenda, Coding and Market Research Reimbursement Analysis for BLINCYTO® (blinatumomab) 7-day Infusion Option; August 2017]. 21. CMS. Local coverage determination (LCD): External infusion pumps (L33794). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcid=33794&ver=121&Date=01%2f01%2f2021&DocID=L33794&SearchType=Advanced&bc=EgAAAAIAAAAA&=>. Accessed June 12, 2024. 22. CMS. External Infusion Pump LCD, March 23, 2023, available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcid=33794&ver=136&>. Accessed June 12, 2024. 23. Centers for Medicare & Medicaid Services (CMS). CY 2017 IPPS Final Rule. <https://www.govinfo.gov/content/pkg/FR-2017-08-14/pdf/2017-16434.pdf>. Accessed June 3, 2024. 24. Medicare Payment Advisory Commission. Hospital acute inpatient services payment system. (Updated October 2020). [http://www.medpac.gov/docs/default-source/payment-basics/medpac\\_payment\\_basics\\_20\\_hospital\\_final\\_sec.pdf?sfvrsn=0](http://www.medpac.gov/docs/default-source/payment-basics/medpac_payment_basics_20_hospital_final_sec.pdf?sfvrsn=0). Accessed June 3, 2024. 25. CMS. Inpatient hospital care. Available at <https://www.medicare.gov/coverage/inpatient-hospital-care>. Accessed June 3, 2024. 26. CMS. PPS-exempt cancer hospitals. [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/PPS\\_Exc\\_Cancer\\_Hospasp.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/PPS_Exc_Cancer_Hospasp.html). Last updated May 6, 2019. Accessed June 3, 2024. 27. Center for Evidence-based Policy. Medicaid and specialty drugs: current policy options. [http://centerforevidencebasedpolicy.org/wp-content/uploads/2018/12/MED\\_Medicaid\\_and\\_Specialty\\_Drugs\\_Current\\_Policy\\_Options\\_Final\\_Sept-9-2016.pdf](http://centerforevidencebasedpolicy.org/wp-content/uploads/2018/12/MED_Medicaid_and_Specialty_Drugs_Current_Policy_Options_Final_Sept-9-2016.pdf). Published June 2016. Accessed June 3, 2024. 28. Johnson D. How pharmacy reimbursement methods have evolved. Washington Healthcare News website. <http://www.wahcnews.com/newsletters/wa-djohnson110.pdf>. Accessed June 3, 2024. 29. CMS. CY 2021 OPPS Final Rule. <https://www.govinfo.gov/content/pkg/FR-2020-12-29/pdf/2020-26819.pdf>. Accessed June 3, 2024. 30. Budget Control Act of 2011. <https://budget.house.gov/sites/democrats.budget.house.gov/files/08.03.11%20Budget%20Control%20Act%20summary.pdf>. Accessed June 3, 2024. 31. Outpatient Services MUE Table 2021 CMS. Facility Outpatient Hospital Services MUE Table - Effective-04-01-2021-Posted March 1, 2021. <https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/MUE>. Accessed June 3, 2024. 32. California Department of Health Care Services. Payment methodology for covered outpatient drugs. <https://www.dhcs.ca.gov/formsandpubs/laws/Documents/Supp-2-to-Attach-419B-3-03-20.pdf>. Accessed June 3, 2024. 33. CMS. 2021 MPFS Final Rule. <https://www.govinfo.gov/content/pkg/FR-2020-12-28/pdf/2020-26815.pdf>. Accessed June 3, 2024. 34. CMS. Local coverage article: External infusion pumps - policy article (A52507). <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52507&ver=73&LCDId=L33794&Date=&DocID=L33794&bc=hAAAAAIAAAAA&=>. Accessed June 3, 2024. 35. Medicare Payment Advisory Commission. Durable medical equipment payment system. [http://www.medpac.gov/docs/default-source/payment-basics/medpac\\_payment\\_basics\\_16\\_dme\\_final.pdf](http://www.medpac.gov/docs/default-source/payment-basics/medpac_payment_basics_16_dme_final.pdf). Revised October 2016. Accessed June 3, 2024. 36. CMS. CY 2020 HH PPS Final Rule. <https://www.govinfo.gov/content/pkg/FR-2020-11-04/pdf/2020-24146.pdf>. Accessed June 3, 2024. 37. Medi-Cal. Provider training 2021: pharmacy billing: home infusion, compound drugs, durable medical equipment & medical supplies. [https://files.medi-cal.ca.gov/pubsdoco/outreach\\_education/workbooks/Workbook\\_ph-b\\_dme.pdf](https://files.medi-cal.ca.gov/pubsdoco/outreach_education/workbooks/Workbook_ph-b_dme.pdf). Accessed June 3, 2024.